TW202130367A - 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途 - Google Patents

結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途 Download PDF

Info

Publication number
TW202130367A
TW202130367A TW110101453A TW110101453A TW202130367A TW 202130367 A TW202130367 A TW 202130367A TW 110101453 A TW110101453 A TW 110101453A TW 110101453 A TW110101453 A TW 110101453A TW 202130367 A TW202130367 A TW 202130367A
Authority
TW
Taiwan
Prior art keywords
antibody
seq
amino acid
histidine
cancer
Prior art date
Application number
TW110101453A
Other languages
English (en)
Chinese (zh)
Inventor
謝瑞霞
馬麗強
汪音爵
Original Assignee
大陸商信達生物製藥（蘇州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商信達生物製藥（蘇州）有限公司 filed Critical 大陸商信達生物製藥（蘇州）有限公司
Publication of TW202130367A publication Critical patent/TW202130367A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
TW110101453A 2020-01-15 2021-01-14 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途 TW202130367A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010043049.0 2020-01-15
CN202010043049 2020-01-15

Publications (1)

Publication Number Publication Date
TW202130367A true TW202130367A (zh) 2021-08-16

Family

ID=76864736

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110101453A TW202130367A (zh) 2020-01-15 2021-01-14 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途

Country Status (2)

Country Link
TW (1) TW202130367A (fr)
WO (1) WO2021143767A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023040999A1 (fr) * 2021-09-18 2023-03-23 江苏康宁杰瑞生物制药有限公司 Composition comprenant un fragment de liaison à l'antigène pd-l1 et son utilisation
WO2023185732A1 (fr) * 2022-03-28 2023-10-05 信达生物制药（新加坡）有限公司 Préparations contenant un anticorps bispécifique anti-claudine18.2/cd3, leur procédé de préparation et leur utilisation
WO2024022414A1 (fr) * 2022-07-29 2024-02-01 舒泰神（北京）生物制药股份有限公司 Préparation d'anticorps monoclonal à haute concentration et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039209T2 (hu) * 2011-03-31 2018-12-28 Merck Sharp & Dohme Antitestek stabil formulációi emberi programozott halálreceptor PD-1 ellen és ezzel kapcsolatos kezelések
RU2731418C2 (ru) * 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
WO2018027524A1 (fr) * 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Formule d'anticorps anti-pd-1.
CA3035378A1 (fr) * 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Compositions d'agents de liaison et de porteuses pd-l1 pour le traitement de cancers
AR112603A1 (es) * 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
CN109966487B (zh) * 2017-12-28 2023-08-25 上海复宏汉霖生物制药有限公司 一种包含抗pd-l1单克隆抗体的药物配制剂
CN110354073B (zh) * 2018-04-09 2021-10-01 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途

Also Published As

Publication number Publication date
WO2021143767A1 (fr) 2021-07-22

Similar Documents

Publication Publication Date Title
TWI761869B (zh) 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
KR20200003107A (ko) 항-lag3 항체의 제제, 및 항-lag3 항체 및 항-pd-1 항체의 공동-제제
WO2021143767A1 (fr) Préparation d'anticorps bispécifique combinant pd-1 et pd-l1 et son utilisation
TWI764097B (zh) 包含抗ｃｄ４７抗體的製劑及其製備方法和用途
WO2021143826A1 (fr) Protéine de mort cellulaire 1 anti-programmée recombinante et préparation d'anticorps bispécifique anti-cluster d'antigène de différenciation 137 et son utilisation
TWI782397B (zh) 重組全人源抗ｔｉｇｉｔ單株抗體製劑及其製備方法和用途
CN114146174B (zh) 抗pd-l1/ox40双特异性抗体制剂及其制备方法和用途
WO2022111612A1 (fr) Préparation comprenant un anticorps bispécifique anti-tigit/pd-1, son procédé de préparation et son utilisation
TWI765311B (zh) 包含抗pd-1/her2雙特異性抗體的製劑及其製備方法和用途
WO2024193670A1 (fr) Préparation contenant un immunoconjugué anti-pd-1/il-2 mutante
CN114007648B (zh) 包含抗lag-3抗体的制剂、其制备方法及其用途
WO2023185732A1 (fr) Préparations contenant un anticorps bispécifique anti-claudine18.2/cd3, leur procédé de préparation et leur utilisation
WO2021228113A1 (fr) Préparation comprenant un anticorps anti-il-23p19, son procédé de préparation et son utilisation
WO2023217234A1 (fr) Composition d'anticorps liquide et son utilisation
CN112675300A (zh) 包含抗gitr抗体的制剂及其制备方法和用途